| Symbol | YUHNF |
|---|---|
| Name | YUHAN CORPORATION |
| Sector | UNDEFINED |
| Region | Asia |
| Industry | - |
| Address | 156-754 Korea, Republic Of 74, Noryangjin-ro Dongjak-gu |
| Telephone | +82-2-828-0181 |
| Fax | — |
| — | |
| Website | http://eng.yuhan.co.kr |
| Incorporation | KR |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | NOT AVAILABLE |
| Reporting Status | International Reporting: Korea Exchange (KRX) |
| CIK | 0001673975 |
| Description | Yuhan has always emphasized research and development as its top corporate priority. The company approaches R&D through innovative, nimble and translational methodologies. This three-fold dynamic allows Yuhan to continue its over-arching commitment to enhancing quality of life. True to the companys founding mission, Yuhan focuses its R&D efforts on developing the kinds of products people need most. By developing therapies for treating inflammatory, autoimmune, oncologic and metabolic diseases, Yuhan has significantly advanced the science and understanding of these prevalent disease processes. This rich body of knowledge and wealth of experience positions Yuhan on the cutting edge for developing unique, innovative, finished products and to partnering successfully with other developers. Additional info from OTC: |
No news found.